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Abstract: The grafting of drugs to the single-walled carbon nanotube (SWCNT) was attained by 
the initial conversion of carboxylic groups in SWCNT to corresponding acyl chlorides. The active 
acyl chlorides in SWCNT were subsequently mixed with chemotherapeutic agents having NH, 
NH2, and OH functional groups to afford the formation of relevant amide and ester, respectively. 
The covalently grafted drugs to SWCNT were identified by infrared and UV–visible spectroscopy 
and transmission electron microscopy methods. From a clinical aspect, the grafting of drugs to the 
SWCNT can be used as a new tool and useful method for potential drug delivery in patients.
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Introduction
Slow release is critically significant in drug delivery for minimizing the amount of drug 
lost before reaching the target. Shell structures and supports can be used for slow delivery 
of drugs and are usually made from organic materials. For example, liposomes,1–3 
microspheres,4 polymeric shells,5 and polymeric micelles6,7 have been well investigated. 
In constructing a drug delivery system from organic materials, the combinations of shell 
or support materials, targeting molecules, and drugs are restricted to ensure stability, 
targeting efficiency, and drug effect. Although, many supporting polymers are expensive, 
this restriction can be reduced by using carbon nanotubes (CNTs).8 On the other hand, 
nanomedicine, which is an emerging bridge linking nanotechnology and advanced 
medical technology, involves the exploration of nanoscaled materials with the aim of 
developing novel types of drug carriers, imaging agents, sensors, etc.9,10
Nanotubes have several properties that make them suitable for use as nanotube-sup-
ported drugs. Functionalized CNTs have been shown in many studies to be able to cross 
cell membranes.11–13 The ability of CNTs to cross cell membranes allowing them to be used 
as carriers is of particular high interest for drug delivery strategies. In targeting the delivery 
of drugs to cells, the drugs are first attached to the carrier by either covalent or noncovalent 
bonding. The drug carrier conjugates are then directed to the targeted cells via passive 
targeting methods (ie, a methodology to increase the target/nontarget ratio of the amounts 
of drugs delivered primarily by minimizing nonspecific interactions with nontarget organs, 
tissues, and cells) or active targeting methods (ie, the method by which the therapeutic agent 
is delivered to tumors by   attaching the agent with a ligand that binds to specific   receptors 
that are   overexpressed on   target cells).14 After reaching the targeted site (organs, tissues, 
or cells), there are 2 possibilities: (1) the drug is internalized (ie, enters the cells) without International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Dovepress
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  internalization of the carrier or (2) both the drug and the carrier 
are   internalized. The latter internalization method has greater 
delivery efficacy because after entering the cells, the intracellular 
  environment will degrade the drug–carrier conjugate, releasing 
drug molecules inside the cells. On the other hand, in the former 
internalization method, the   extracellular environment helps 
degrade drug–carrier   conjugates, and the drug will then cross the 
lipid   membrane to enter the cells. CNTs with the ability to cross 
cell   membranes are good candidates to serve as drug delivery 
carriers to cells with high efficacy.15 Also, negative mutagenic 
and clastogenic potentials suggest that single-walled carbon 
nanotubes (SWCNTs) and single-walled carbon nanohorns 
(SWCNHs) are not carcinogenic. For example, the acute per 
oral   toxicity of SWCNHs was found to be quite low.16–18 The 
lethal   dosage for rats was more than 2,000 mg/kg of body 
weight. Intratracheal instillation tests revealed that SWCNHs 
rarely damaged rat lung tissue in a 90-day test period, although 
black pigmentation due to the accumulation of SWCNHs was 
observed.19 In recent years, biological applications for carbon 
nanomaterials, including SWCNHs and fullerene, have come 
under close scrutiny.11,20–24
SWCNHs and SWCNTs have extensive surface areas. 
Multitudes of horn interstices in SWCNHs enable large 
numbers of guest molecules to be adsorbed in a nonbonded 
way; however, to the best of our knowledge, the covalent 
grafting of drugs to the SWCNT has not been reported so 
far. Herein, we report the ability of SWCNTs for the covalent 
grafting of drugs to their active sites (Figure 1).
The medicinal standpoint of this present research is cova-
lent grafting of drugs to SWCNTs, which can be considered 
a new method for potential drug delivery. This would be 
achievable by preparing several pastes that can be applied on 
the skin similar to a label. Hydrolysis reaction occurs, and the 
drug is absorbed through the skin long time intervals after 
the application of the paste.25 This process, therefore, enables 
the slow administration of medications for longer periods. 
This can help patients who have   problems associated with 
oral administration and injection of drugs.
The solubility of products obtained in this work is also an 
important subject. The solubility of SWCNTs in aqueous and 
organic solvents has been previously studied by functionalizing 
the SWCNTs with various organic moieties.26
Materials and methods
Materials
The pure SWCNTs in their closed cap shape without functional 
groups were purchased from Petrol Co. (Tehran, Iran) (Figure 2). 
SOCl2, HCl, H2SO4, HNO3, H2O2 (30 wt%, aq), deionized 
water, NaH (80%), anhydrous dimethylformamide (DMF), 
CaH2, anhydrous Na2SO4, and phosphate-buffered saline (PBS; 
pH = 1.3) were obtained from Sigma Aldrich and Merck. Cel-
lophane membrane dialysis bag was purchased from Polymer 
Co. (Tehran/Iran). Drugs, such as amantadine, metformin, 
gabapentin, betahistine, dipyridamol, lisinopril, and atorvastatin, 
were purchased from Sobhan Darou Co. (Tehran, Iran).
Functionalization of sWcNTs
To functionalize the SWCNT with drugs having amino and/
or hydroxyl moieties, we followed a methodology already 
demonstrated by several literatures.26–30
The first step was cracking and oxidation of the SWCNTs. 
For every 0.1 g of full-length SWCNT, 50 mL mixture of 
3:1 (vol/vol) concentrated H2SO4 and HNO3 was added, and 
the SWCNT–acid mixture was then subjected to reflux at 
temperature between 65°C and 70°C for 30 hours.
When the desired time had elapsed, the SWCNT–acid 
mixture was diluted with a minimum amount of deionized 
water (250 mL). The resulting diluted nanotube–acid mixture 
was then filtered using a 0.45 µm   polytetrafluoro-ethylene 
filter (PTFE–millipore) to leave a SWCNT filter cake. 
The nanotubes were then rinsed with water until a pH above 
5 was obtained. Final rinsing was done using ethanol, and 
the resulting filter cake was suspended in a 4:1 mixture of 
H2O2 (30 wt%, aq) and H2SO4. The suspension was refluxed 
C
O
X SWCNT Drug
X = O, NH, NR
Drug: Amantadine, Metformin, Gabapentin,
Betahistine, Dipyridamol, Lisinopril, Atorvastatin
Figure 1 covalent grafting of various drugs to the sWcNT.
Figure 2 scanning electron microscopy (seM) images of sWcNT (without functional 
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for 2 hours at 70°C to crack the SWCNTs in shorter lengths 
and, thereby, produce a larger number of opened caps 
for carboxylation. Concentrated HCl was then added to 
the suspension and briefly sonicated to remove the metal 
catalyst,27–29 which resulted in the introduction of terminal 
carboxyl functional groups, as indicated by infrared mea-
surement (ν(C=O) = 1,737 cm−1; spectrum A, Figure 4). The 
precipitate was stored in a vacuum oven at 180°C to remove 
the water.
The second step was the generation of the acyl chloride 
functional groups by suspending the purified SWCNT 
(prepared from the first step) in a solution of freshly distilled 
thionyl chloride (SOCl2) and DMF, which was previously 
kept in anhydrous Na2SO4 for 72 hours and distilled in 
the presence of CaH2. The amounts used in this particular 
example were 20 mL SOCl2 and 1 mL DMF per 0.1 g of 
SWCNT. This suspension was stirred at 65°C for 24 hours. 
The solid was then separated by filtration and washed with 
superdried tetrahydrofuran (THF) to remove excess of SOCl2. 
Subsequently, it was dried in vacuum at room temperature 
for 5 minutes. The final product was then subjected to 
functionalization with various drugs.
Drugs having free OH, NH2, or NH groups (drug-to-
SWCNT weight ratio was 15:1)30 were mixed with 1 mL 
solution of DMF and NaH (80%) and then stirred for 1 hour. 
The obtained acyl chloride SWCNTs were then added to 
the suspension. The reaction mixture was kept at 120°C for 
5 days. The solid was then separated by filtration and washed 
with deionized water for several times.
The reaction of the drugs with SWCNT and the potential 
structure of grafted drugs to SWCNTs are summarized in 
Table 1.
After stirring, a black solid was obtained, which was 
soluble in DMF and dimethylsulfoxide (DMSO), less soluble 
in H2O and CH3CN, and insoluble in CHCl3, CH2Cl2, acetone, 
diethyl ether, and hexane (Figure 3A and B).
Table 1 covalent grafting of various drugs to sWcNT
Entry  Drug scaffold (a)  Drug name (properties)
Amantadine  1
2
3
4
5
6
7
NH2
Antiviral and antiparkinson 
HN
O
Metformin 
N
H
NH
N(CH3)2
NH
H2N
Antidiabetic  N
H
NH
N(CH3)2
NH
HN
O
Gabapentin 
COOH H2N
Antiepileptic 
COOH N
H
O
Betahistine 
N N
H3C
H
Antivertigo  N N
CH3
O
Dipyridamol 
N
N
N
N
N
N
N
OH
OH
N
OH
HO
Antiplatelet 
N
N
N
N
N
N
N
OH
OH
N
OH
O
O
Lisinopril 
HN
O
N
H2N(H2C)2
CO2H
CO2H
Antihypertensive 
HN
O
N
HN(H2C)2
CO2H
CO2H
O
Atorvastatin 
N
CO2H
OH OH
N
H
O
F
Blood cholesterol lowering  N
CO2H
HO
O
NH
O
F
O
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Results and discussion
We characterized the functional groups present in the cova-
lent drugs grafted to SWCNT by IR and UV–visible (UV–vis) 
spectroscopy and transmission electron microscopy (TEM) 
methods after various treatments.
After the initial acid treatment of SWCNT with a   mixture 
of H2SO4 and HNO3 followed by HCl, the spectrum A was 
observed (Figure 4). The IR spectrum B is pertaining to 
pure betahistine, and the IR spectrum C (Figure 3) shows 
the grafted SWCNT–betahistine (entry 4b, Table 1). The 
band corresponding to the carboxylic groups present in the 
acid-treated SWCNT (1,737 cm−1; IR spectrum A, Figure 4) 
is gradually replaced by bands corresponding to amide bonds 
(1,663 cm−1; IR spectrum C, Figure 4). Band at 1,699 cm−1 is 
attributed to water (IR spectrum A, Figure 4). Table 2 sum-
marizes the main bands observed in IR spectra of grafted 
drugs to SWCNTs.
The UV–vis absorption spectrum of betahistine (Figure 5) 
displays a loss of features compared with that of SWCNT 
indicating a disruption in the electronic structure of nanotubes 
due to the adsorption of betahistine on SWCNT.
TEM studies have revealed the successful grafting of 
betahistine and other drugs to SWCNT (Figure 6). A large 
number of the bundles are abundant in functionalized 
SWCNTs, which are indicated by arrows.
In vitro release of betahistine  
from grafted sWcNT–betahistine
Drug releasing from the grafted SWCNT–drug is indeed a 
hydrolysis reaction, which involves breaking of amide bond 
in acidic buffer (PBS; pH = 1.3) at 37°C. The   powdered 
grafted SWCNT–betahistine (0.02 g) was added into a cel-
lophane membrane dialysis bag. The bag was closed and 
transferred into a flask containing 50 mL of acid buffer. The 
release of betahistine from grafted SWCNT–betahistine 
was followed by UV–vis spectroscopy. Figure 7A illustrates 
the cumulative dose of betahistine released from grafted 
SWCNT–betahistine.
Drug loading of betahistine
A weighed quantity of microspheres was hydrolyzed in 50 
mL acid buffer (PBS; pH = 1.3). After suitable dilution, the 
absorbance of samples was measured by UV–vis spectropho-
tometer at λ = 264 nm. The amount of drug was determined 
from the standard plot of betahistine. The amount of betahis-
tine loaded in SWCNTs’ microspheres was determined after 
complete hydrolysis and was found to be 73 wt%.
In vitro release of dipyridamol  
from grafted sWcNT–  dipyridamol
The release of dipyridamol from the grafted SWCNT–
dipyridamol was studied using the same method, which has 
been described earlier for SWCNT–betahistine. Figure 7B 
illustrates the cumulative dose of dipyridamol released from 
grafted SWCNT–dipyridamol.
Drug loading of dipyridamol
Drug loading of dipyridamol (λ = 262 nm was studied 
using the same method, which has been described earlier 
for SWCNT–betahistine, and was found to be 65 wt%. It 
is interesting to note that the release of dipyridamol from 
SWCNTs was achieved more smoothly than that of betahis-
tine from SWCNT–betahistine. This can be easily deduced 
by comparing Figure 7A with Figure 7B.
Conclusion
In summary, the covalent grafting of some known drugs with 
different pharmaceutical activities to SWCNTs was achieved 
by the formation of amides and esters from the drugs having 
free hydroxyl and/or amino groups mixed with the prepared 
acyl chloride in SWCNTs. The covalent grafting of drugs 
increases the solubility of SWCNTs in both aqueous and 
organic solvents. In vitro release of betahistine and dipyri-
damol from their corresponding grafted SWCNT adducts 
was studied, which indicates that drug release can occur 
smoothly from covalent SWCNT–drug adducts   during long 
time intervals, and this can be considered a useful method 
for drug delivery.
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Figure 4 Infrared spectra of A) sWcNT-cOOh, B) pure betahistine, and C) grafted sWcNT–betahistine.
Table 2 Infrared absorption bands obtained from the acid-treated sWcNTs and drugs grafted to sWcNTs’ solid samples
Compound Region (cm-1) Band assignments
sWcNT-cOOh 1,737 carboxylic acid c=O stretching vibration of sWcNTs
3,407 carboxylic acid Oh stretching vibration of sWcNTs
1b 1,630 Amide c=O stretching vibration
2b 1,660 Amide c=O stretching vibration
3b 1,630 Amide c=O stretching vibration
4b 1,663 Amide c=O stretching vibration
5b 1,626 ester c=O stretching vibration
6b 1,656 Amide c=O stretching vibration
7b 1,713 ester c=O stretching vibrationInternational Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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